Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

BACKGROUND: The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research. METHODS: Overall response rate (ORR) was extracted from phas...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Carbognin, Luisa, Pilotto, Sara, Milella, Michele, Vaccaro, Vanja, Brunelli, Matteo, Caliò, Anna, Cuppone, Federica, Sperduti, Isabella, Giannarelli, Diana, Chilosi, Marco, Bronte, Vincenzo, Scarpa, Aldo, Bria, Emilio, Tortora, Giampaolo
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472786/
https://ncbi.nlm.nih.gov/pubmed/26086854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0130142
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares